Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015

Mary B. Daly(Fox Chase Cancer Center), Robert Pilarski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer E. Axilbund(Sidney Kimmel Comprehensive Cancer Center), Michael P. Berry(St. Jude Children's Research Hospital), Saundra S. Buys(University of Utah), Beth Crawford(UCSF Helen Diller Family Comprehensive Cancer Center), Meagan Farmer(University of Alabama at Birmingham), Susan Friedman(Facing Our Risk of Cancer Empowered), Judy E. Garber(Dana-Farber Brigham Cancer Center), Seema Khan(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Catherine Klein(University of Colorado Cancer Center), Wendy Kohlmann(University of Utah), Allison W. Kurian(Cancer Institute (WIA)), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Lisa Madlensky(UC San Diego Health System), P. Kelly Marcom(Cancer Institute (WIA)), Sofía D. Merajver(University of Michigan), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Tuya Pal(Susan Thompson Buffett Foundation), Huma Q. Rana(Dana-Farber Brigham Cancer Center), Gwen Reiser(Novartis (Switzerland)), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Kristen M. Shannon(Massachusetts General Hospital), Elizabeth M. Swisher(Seattle Cancer Care Alliance), Nicoleta Voian(Roswell Park Comprehensive Cancer Center), Jeffrey N. Weitzel(City of Hope), Alison J. Whelan(Barnes-Jewish Hospital), Myra Wick(WinnMed), Georgia L. Wiesner(Breast Cancer Research Foundation), Mary A. Dwyer(National Comprehensive Cancer Network), Rashmi Kumar(National Comprehensive Cancer Network), Susan Darlow(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
February 1, 2016
Cited by 292

Abstract

The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling and risk assessment and management for hereditary cancer syndromes. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer and are intended to assist with clinical and shared decision-making. These NCCN Guidelines Insights summarize major discussion points of the 2015 NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meeting. Major discussion topics this year included multigene testing, risk management recommendations for less common genetic mutations, and salpingectomy for ovarian cancer risk reduction. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer.


Related Papers

No related papers found

Powered by citation graph analysis